Biogen submits application to FDA for factor IX therapy for Hemophilia B Biogen Idec says it recently submitted a Biologics License Application to the U.S. Food and Drug Administration for the marketing approval of recombinant factor IX Fc fusion protein for the treatment of hemophilia B. rFIXFc is the first product candidate in a new class of long-lasting clotting factor therapies that are being developed with the goals of reducing the burden of treatment for this condition and enhancing protection from bleeding. The regulatory submission was based on results from B-LONG, the largest registrational phase 3 clinical study in hemophilia B to date. Biogen Idecís BLA submission to the U.S. FDA for rFVIIIFc for use in patients with hemophilia A is on track for filing in 1H 2013.
Biogen price target raised to $443 from $376 at Stifel Stifel increased its price target on Biogen after listening to updates on the company's pipeline during its Q4 results conference call. The firm believes that the results of the clinical trials of Biogen's anti-LINGO in acute optic neuritis nd BIIB037 in Alzheimerís disease were "highly positive." The firm says that the company's MS franchise is "safe and sound." It keeps a Buy rating on the shares.
Biogen price target raised to $410 from $383 at Citigroup Citigroup raised its price target for Biogen shares to $410 saying the company's 2015 guidance has upside. Citi keeps a Buy rating on Biogen following the company's Q4 results.
Biogen price target raised to $421 from $386 at Piper Jaffray Piper Jaffray raised its price target for Biogen shares to $421 citing the company's "solid" Q4 results and 2015 outlook. Piper reiterates an Overweight rating on the stock.
Leerink biotech analysts hold an analyst/industry conference call Biotech Analyst Schwartz discusses Biogen Idec BIIB037 and whether 2015 will be the year when Amyloid Beta is finally validated as a disease-modifying target in Alzheimer's Disease on an Analyst/Industry conference call to be held on February 3 at 2 pm.